Elimination of Aicardi–Goutières syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication

[1]  Brenda J. Crowe,et al.  Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial , 2021, The Lancet Respiratory Medicine.

[2]  T. Dörner,et al.  Altered increase in STAT1 expression and phosphorylation in severe COVID‐19 , 2021, medRxiv.

[3]  J. Casanova,et al.  Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs , 2021, The Journal of experimental medicine.

[4]  Jourdan K. Ewoldt,et al.  SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway , 2021, Journal of virology.

[5]  Guilin Wang,et al.  Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics , 2021, The Journal of experimental medicine.

[6]  A. Fassati,et al.  The Role of Capsid in the Early Steps of HIV-1 Infection: New Insights into the Core of the Matter , 2021, Viruses.

[7]  Qian Li,et al.  Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway , 2021, Frontiers in Immunology.

[8]  S. Nisole,et al.  SARS-CoV-2 Triggers an MDA-5-Dependent Interferon Response Which Is Unable To Control Replication in Lung Epithelial Cells , 2021, Journal of Virology.

[9]  Sangkyu Park,et al.  Differential Signaling and Virus Production in Calu-3 Cells and Vero Cells upon SARS-CoV-2 Infection , 2021, Biomolecules & therapeutics.

[10]  Helio T. Navarro,et al.  Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia , 2020, Nature.

[11]  Cameron R. Wolfe,et al.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.

[12]  S. Perlman,et al.  SARS-CoV-2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells. , 2020, The Journal of infectious diseases.

[13]  V. Thiel,et al.  Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.

[14]  Brenda J. Crowe,et al.  Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways , 2020, Lupus science & medicine.

[15]  Vineet D. Menachery,et al.  Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV , 2020, Journal of Virology.

[16]  L. Ren,et al.  Activation and evasion of type I interferon responses by SARS-CoV-2 , 2020, Nature Communications.

[17]  F. Shan,et al.  A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19 , 2020, EClinicalMedicine.

[18]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[19]  S. Nisole,et al.  Interplay between SARS-CoV-2 and the type I interferon response , 2020, PLoS pathogens.

[20]  R. Schinazi,et al.  Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  F. Weber,et al.  Inhibition of SARS–CoV-2 by type I and type III interferons , 2020, The Journal of Biological Chemistry.

[22]  C. Scagnolari,et al.  Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection , 2020, The Journal of Infectious Diseases.

[23]  M. Fellhauer,et al.  The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation , 2020, Leukemia.

[24]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[25]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[26]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[27]  Slobodan Paessler,et al.  Antiviral activities of type I interferons to SARS-CoV-2 infection , 2020, Antiviral Research.

[28]  O. Tsang,et al.  Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.

[29]  Natacha S. Ogando,et al.  SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology , 2020, bioRxiv.

[30]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues , 2020, SSRN Electronic Journal.

[31]  B. Koo,et al.  Norovirus Replication in Human Intestinal Epithelial Cells Is Restricted by the Interferon-Induced JAK/STAT Signaling Pathway and RNA Polymerase II-Mediated Transcriptional Responses , 2020, mBio.

[32]  Vineet D. Menachery,et al.  Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. , 2020, bioRxiv.

[33]  M. Peppelenbosch,et al.  MDA5 against enteric viruses through induction of interferon-like response partially via the JAK-STAT cascade. , 2020, Antiviral research.

[34]  S. Rahman,et al.  Web of interferon stimulated antiviral factors to control the influenza A viruses replication. , 2019, Microbial pathogenesis.

[35]  M. Bros,et al.  RhoA as a Key Regulator of Innate and Adaptive Immunity , 2019, Cells.

[36]  D. Missé,et al.  SAMHD1 Enhances Chikungunya and Zika Virus Replication in Human Skin Fibroblasts , 2019, International journal of molecular sciences.

[37]  Fan Luo,et al.  IFN-λs inhibit Hantaan virus infection through the JAK-STAT pathway and expression of Mx2 protein , 2019, Genes & Immunity.

[38]  M. Santiago,et al.  SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-κB and interferon pathways , 2018, Proceedings of the National Academy of Sciences.

[39]  D. Ivanov,et al.  A SAMHD1 mutation associated with Aicardi–Goutières syndrome uncouples the ability of SAMHD1 to restrict HIV‐1 from its ability to downmodulate type I interferon in humans , 2017, Human mutation.

[40]  R. Schinazi,et al.  SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. , 2016, Virology.

[41]  J. Rehwinkel,et al.  Restriction by SAMHD1 Limits cGAS/STING-Dependent Innate and Adaptive Immune Responses to HIV-1 , 2016, Cell reports.

[42]  Nan Yan,et al.  RNase H2 catalytic core Aicardi-Goutières syndrome–related mutant invokes cGAS–STING innate immune-sensing pathway in mice , 2016, The Journal of experimental medicine.

[43]  Yoshiya Tanaka,et al.  Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study , 2016, The Journal of Rheumatology.

[44]  D. Yoo,et al.  Suppression of type I interferon production by porcine epidemic diarrhea virus and degradation of CREB-binding protein by nsp1 , 2016, Virology.

[45]  Y. Crow,et al.  Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.

[46]  H. Takaki,et al.  RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and attenuates the innate immune response. , 2015, Cell reports.

[47]  Robert A. Domaoal,et al.  Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses , 2014, Retrovirology.

[48]  Krystal L. Matthews,et al.  The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity , 2014, Virology Journal.

[49]  Mones Abu-Asab,et al.  SARS-Coronavirus Open Reading Frame-9b Suppresses Innate Immunity by Targeting Mitochondria and the MAVS/TRAF3/TRAF6 Signalosome , 2014, The Journal of Immunology.

[50]  R. Schinazi,et al.  dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages , 2014, Retrovirology.

[51]  O. Ohara,et al.  Aicardi-Goutières syndrome is caused by IFIH1 mutations. , 2014, American journal of human genetics.

[52]  A. Vanderver,et al.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study , 2013, The Lancet Neurology.

[53]  Eui Tae Kim,et al.  SAMHD1 Restricts Herpes Simplex Virus 1 in Macrophages by Limiting DNA Replication , 2013, Journal of Virology.

[54]  Baek Kim,et al.  Host Factor SAMHD1 Restricts DNA Viruses in Non-Dividing Myeloid Cells , 2013, PLoS pathogens.

[55]  Y. Guan,et al.  Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures , 2013, Journal of Virology.

[56]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[57]  John H Livingston,et al.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature , 2012, Nature Genetics.

[58]  Baek Kim,et al.  The Vpx Lentiviral Accessory Protein Targets SAMHD1 for Degradation in the Nucleus , 2012, Journal of Virology.

[59]  R. Naumann,et al.  Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity , 2012, The Journal of experimental medicine.

[60]  Baek Kim,et al.  Tight Interplay among SAMHD1 Protein Level, Cellular dNTP Levels, and HIV-1 Proviral DNA Synthesis Kinetics in Human Primary Monocyte-derived Macrophages* , 2012, The Journal of Biological Chemistry.

[61]  Baek Kim,et al.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates , 2012, Nature Immunology.

[62]  B. Sobhian,et al.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.

[63]  Lina Sun,et al.  The location of endogenous wild-type p53 protein in 293T and HEK293 cells expressing low-risk HPV-6E6 fusion protein with GFP. , 2010, Acta biochimica et biophysica Sinica.

[64]  T. Wurdinger,et al.  Real-Time Monitoring of Nuclear Factor κB Activity in Cultured Cells and in Animal Models , 2009, Molecular imaging.

[65]  W. Miller,et al.  Retinoids inhibit measles virus through a type I IFN‐dependent bystander effect , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  Jonathan C. Fuller,et al.  Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response , 2009, Nature Genetics.

[67]  L. Ye,et al.  Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[68]  Cun-Yu Wang,et al.  MAVS Self-Association Mediates Antiviral Innate Immune Signaling , 2009, Journal of Virology.

[69]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[70]  A. Green,et al.  Clinical and molecular phenotype of Aicardi-Goutieres syndrome. , 2007, American journal of human genetics.

[71]  M. Desforges,et al.  Activation of human monocytes after infection by human coronavirus 229E , 2007, Virus Research.

[72]  C. Ponting,et al.  Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection , 2006, Nature Genetics.

[73]  D. Barnes,et al.  Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus , 2006, Nature Genetics.

[74]  Y. Lau,et al.  Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.

[75]  Y. Guan,et al.  Cytokine Responses in Severe Acute Respiratory Syndrome Coronavirus-Infected Macrophages In Vitro: Possible Relevance to Pathogenesis , 2005, Journal of Virology.

[76]  C. Der,et al.  GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.

[77]  I. Krägeloh-Mann,et al.  Cerebrospinal fluid pterins and folates in Aicardi-Goutières syndrome , 2003, Neurology.

[78]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[79]  J. Aicardi,et al.  A Progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis , 1984, Annals of neurology.

[80]  A. Heredia,et al.  Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.